Nuvoton Technology Corporation (4919)

Overview

Founded in 1967 and based in Yongin-Si, South Korea, Green Cross Holdings Corporation specializes in biotechnology, focusing on the production of prescription and over-the-counter drugs, along with a range of services designed to support the pharmaceutical industry. This includes aseptic fill and finish services for drug manufacturing and comprehensive pharmaceutical logistics. The company emphasizes research and development, working on treatments for a multitude of diseases and conditions, and forming partnerships with biotech entities and academic institutions to push forward the development of new drugs and technologies. Their efforts span across various therapeutic areas, aiming to contribute significantly to advancing medical care and treatment options.

Products and Services

Green Cross Holdings Corporation offers a diverse portfolio of products and services across several key domains, including:

• Prescription Drugs and Over the Counter Drugs - The company provides a wide array of medications designed to treat various illnesses, ensuring they meet the healthcare needs of patients.
• Aseptic Fill and Finish Services - These services are critical for the sterile manufacturing process of drugs, ensuring safety and efficacy in drug delivery.
• Pharmaceutical Logistics Services - Green Cross Holdings facilitates comprehensive logistics solutions, managing the distribution and supply chain for pharmaceuticals effectively.
• Plasma Derivatives - The company works on developing plasma-derived products for treating conditions such as von Willebrand disease and primary immunodeficiency.
• Vaccines - Their research includes developing vaccines for various diseases, including mRNA flu, anthrax, tetanus, diphtheria, pertussis, tuberculosis, and varicella, aiming to prevent these conditions.
• Recombinant Treatments - Focused on genetic disorders and diseases, Green Cross Holdings is developing treatments for conditions such as acquired thrombotic thrombocytopenic purpura, Fabry disease, hemophilia, hunter syndrome, and colon cancer.
• Small Molecules - The company is also involved in researching small molecule treatments for genetic disorders like gangliosidosis and Alagille syndrome, exploring new pathways for therapeutic intervention.

The company’s exhaustive efforts in research and development, alongside its partnerships and collaborations, underscore its commitment to innovating healthcare solutions, providing advanced treatment options, and contributing to global public health advancements.